pyrazines has been researched along with alectinib in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Hussar, DA | 1 |
Adachi, J; Araki, M; Friboulet, L; Fujita, N; Katayama, K; Katayama, R; Kukimoto-Niino, M; Kutkowska, J; Ma, B; Maruyama, K; Mizuta, H; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sagae, Y; Sasakura, Y; Shirouzu, M; Simizu, S; Takagi, S; Takemoto, A; Tamai, K; Watanabe, K; Yanagitani, N | 1 |
Mungmunpuntipantip, R; Wiwanitkit, V | 1 |
3 other study(ies) available for pyrazines and alectinib
Article | Year |
---|---|
New Drugs 2017, part 3.
Topics: Acetamides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antitoxins; Bridged Bicyclo Compounds, Heterocyclic; Carbazoles; Chenodeoxycholic Acid; Drug Approval; Humans; Indoles; Morpholinos; Oligonucleotides; Piperidines; Polydeoxyribonucleotides; Pyrazines; Sulfonamides; United States; United States Food and Drug Administration | 2017 |
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Topics: Aminopyridines; Aniline Compounds; Animals; Apoptosis; Benzamides; Carbazoles; Cell Line; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasm Recurrence, Local; Piperidines; Proto-Oncogene Proteins; Pyrazines; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2021 |
Alectinib, COVID-19 and favipiravir.
Topics: Amides; Carbazoles; COVID-19; Humans; Piperidines; Pyrazines; SARS-CoV-2 | 2021 |